Aptorum Group Limited

APM

KYG6096M1226

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.85 ^USD	-20.29%		-16.30%	+57.23%

Apr. 30	Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Top Midday Gainers	MT

Aptorum Group Limited Announces Resignation of Dr. Angel Ng as Chief Operating Officer

August 27, 2021 at 04:03 pm EDT

Aptorum Group Limited announced that resignation of Dr. Angel Ng as Chief Operating Officer. Angel's resignation did not result from any disagreement regarding any matter related to the Company's operations, policies or practices.

Latest news about Aptorum Group Limited

Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Top Midday Gainers	Mar. 06	MT
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.	Mar. 05	CI
Top Premarket Decliners	Jan. 29	MT
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 22	CI
Aptorum Group Limited Announces Chief Executive Changes	Nov. 30	CI
Aptorum Group Limited Announces Management Changes	Nov. 30	CI
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation	23-09-10	CI
Top Premarket Decliners	23-08-28	MT
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market	23-08-10	MT
Top Premarket Gainers	23-07-18	MT
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development	23-06-30	CI
Aptorum Group Limited announced that it has received $3 million in funding	23-06-27	CI
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma	23-06-22	CI
Biopharmaceutical Group Aptorum to Delist from Euronext Paris	23-06-12	MT
Top Premarket Decliners	23-05-18	MT
Top Midday Decliners	23-05-08	MT
Looming Economic Data Prompt Quiet Premarket Action for US Equity Futures	23-05-08	MT
Top Premarket Decliners	23-05-08	MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq -- Shares Slump in Premarket	23-05-08	MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq	23-05-08	MT
Top Premarket Gainers	23-05-03	MT
Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Aptorum, URF Holding Group to Combine in Reverse Takeover	23-03-27	MT
URF Holding Group Limited entered into a non-binding Letter of Intent and Term Sheet to acquire Aptorum Group Limited for $40 million in a reverse merger transaction.	23-03-26	CI

Chart Aptorum Group Limited

Duration

Period

More charts

Company Profile

Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

Sector

Pharmaceuticals

Calendar

2024-09-09 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
APTORUM GROUP LIMITED	+57.23%	21.06M
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+32.82%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.64%	244B
ROCHE HOLDING AG	-4.13%	208B
NOVARTIS AG	+10.63%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals